A Narrative Review of Use of Drugs for Prevention of Malaria
Abstract
An estimated 3.4 billion people are at risk of malaria. The use of drugs for prevention of malaria among people at risk of the disease has been practiced since centuries in the form of chemoprophylaxis, intermittent preventive treatment (IPT) or Mass Drug Administration (MDA). Articles were retrieved using search from Cochrane database of Systematic reviews and Google search. Keywords used included “malaria chemoprophylaxis”,” Drugs for prevention of Malaria” and “guidelines for prevention of Malaria”. Chemoprophylaxis is an effective strategy for a limited time but it does not offer lifelong protection. The 6 drugs in the WHO guidelines for chemoprophylaxis of Malaria are Atovaquine Proguanil combination, Chloroquine, Chloroquine- Proguanil combination, Doxycycline, Mefloquine and Proguanil. The guidelines for India recommend Doxycycline for short stay and Mefloquine for longer stay. Regimens recommended for use in South Africa include Mefloquine, Doxycycline or Atovaquone-proguanil. Though MDA has gone into disrepute because of its ability to produce drug resistance, examples of successful elimination using MDA exist. IPT given to women in first and second pregnancies reduced the number of women with severe anaemia, perinatal deaths and increased the birth weight of babies. WHO recommended IPT for children consists of Sulfadoxine-Pyrimethamine and Amodiaquine given to children between 3-59 months. Reviews of IPT in children show benefits in reducing the number of malaria episodes and preventing severe disease and deaths. IPT in infants show 30% reduction in incidence. More research is required in prevention of malaria for bringing less costly drugs with limited side effects. Priority should be given to the use of non pharmacological measures to reduce the burden of disease, so that we can prevent the need for using drugs for prevention of malaria.
When publishing with Kerala Medicial Journal (KMJ), authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Work includes the material submitted for publication and any other related material submitted to KMJ. In the event that KMJ does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).
The assignment of rights to KMJ includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.
